April 2000
Worldwide Biotech;Apr2000, Vol. 12 Issue 4, p5
Trade Publication
Reports that Reminyl or galantine, a symptomatic treatment for dementia of the Alzheimer's type, has received regulatory approval from the European Union.


Related Articles

  • Ethical Issues Relating to the Use of Antimicrobial Therapy in Older Adults. Marcus, Esther-Lee; Clarfield, A. Mark; Moses, Allon E. // Clinical Infectious Diseases;11/15/2001, Vol. 33 Issue 10, p1697 

    This article aims to review the literature relating to the ethics of antibiotic prescription decisions in older adults and to offer some suggestions as to how one might approach these difficult problems. According to many studies, most patients and their family members wish to receive...

  • Benefits and risks of atypical and psychotics in dementia.  // Pulse;3/19/2005, Vol. 65 Issue 11, p48 

    Discusses the benefits and risks of atypical antipsychotics in dementia. Effectiveness of atypical antipsychotics in treating behavioral symptoms; Risks associated with the drug; Recommendation to stop the administration of the drug once the behavior has settled. INSET: '3T' approach for...

  • Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;4/27/2004, Vol. 170 Issue 9, p1395 

    Issues a warning about an increased incidence of cerebrovascular events involving antipsychotic drug olanzapine. Statistics on incidence rates in dementia trials; Relative risk of a cerebrovascular event among patients; Options that physicians should consider when prescribing antipsychotic...

  • Increased mortality among elderly patients with dementia using atypical antipsychotics. Singh, Sonal; Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;8/2/2005, Vol. 173 Issue 3, p252 

    Discusses research being done on the use of atypical anti-psychotic drugs in the treatment of behavioral and psychological symptoms of dementia. Reference to a study by P. E. Lee, S. S. Freedman et al, published in the 2004 issue of the "British Medical Journal"; Incidence of death among...

  • Donepezil.  // AHFS Consumer Medication Information;Jun2020, p1 

    Donepezil is used to treat dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) associated with Alzheimer's disease (AD; a brain disease that slowly destroys the memory and the...

  • A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia. Atti, A.R.; Ferrari Gozzi, B.; Zuliani, G.; Bernabei, V.; Scudellari, P.; Berardi, D.; De Ronchi, D.; Tarricone, I.; Menchetti, M. // International Psychogeriatrics;Jan2014, Vol. 26 Issue 1, p19 

    Background:In clinical practice, Second Generation Antipsychotics (SGAs) are often used as first-line treatment for the Behavioral and Psychological Symptoms of Dementia (BPSD) in older adults due to their fewer neurological adverse events and similar effectiveness compared with First Generation...

  • An Exploratory Open-Label Trial of Ziprasidone for the Treatment of Behavioral and Psychological Symptoms of Dementia. Rocha, Fábio Lopes; Hara, Cláudia; Ramos, Melissa Guarieiro; Kascher, Gustavo Guimarães; Santos, Milena Antunes; De Oliveira Lança, Gleida; Scoralick, Francisca Magalhães // Dementia & Geriatric Cognitive Disorders;2006, Vol. 22 Issue 5/6, p445 

    Objective: To evaluate the efficacy and tolerability of ziprasidone in behavioral and psychological symptoms of dementia. Method: A 7-week open-label trial of ziprasidone. Results: Of the 25 patients who participated, 15 completed the study. The main reason for discontinuation was adverse...

  • Key Issues in Evolving Dementia Care: International Theory-based Policy and Practice. DICKINSON, CLAIRE // Ageing & Society;May2013, Vol. 33 Issue 4, p720 

    A review of the book "Key Issues in Evolving Dementia Care: International Theory-based Policy and Practice," edited by Anthea Innes, Fiona Kelly, and Louise McCabe is presented.

  • Management of behavior problems in the demented patient. Stewart, Jonathan T. // American Family Physician;12/1/1995, Vol. 52 Issue 8, p2311 

    Discusses the management of behavior problems in demented patients in the United States. Specific behaviors of demented patients; Etiology of behavioral decompensation; Drugs used to treat depression in patients with dementing illnesses; Working with families of patients with dementing illness.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics